Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88
Benzinga Newsdesk 2 years ago
NewsUpgradesPrice TargetAnalyst Ratings
Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raises the price target from $2 to $6.88.
Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raises the price target from $2 to $6.88.